Pharmacokinetic profiles of current therapies for Alzheimer's disease: Implications for switching to galantamine

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Although no pharmacologic treatments have been proved to alter the pathology of Alzheimer's disease, acetylcholinesterase inhibitor (AChEI) therapy offers symptomatic improvements in or delays in the progression of cognitive, behavioral, and functional deficits. Tacrine, donepezil, rivastigmine, and galantamine are the best studied agents in this class. These drugs have varying pharmacokinetic, safety, and tolerability profiles that can affect patient outcomes. Specifically, certain metabolic parameters (ie, half-life and route of metabolism/elimination) can affect a drug's tolerability and become important when a switch from one agent to another is contemplated. The mechanism of action of galantamine, the most recently approved AChEI, varies from that of the other AChEIs in that it has allosteric modulating activity at nicotinic receptors in addition to its ability to inhibit acetylcholinesterase. Benefits of this dual mode of action on the effects of the disease have been suggested.

Original languageEnglish
JournalClinical Therapeutics
Volume23
Issue numberSUPPL. A
DOIs
StatePublished - 2001

Fingerprint

Galantamine
Rivastigmine
Cholinesterase Inhibitors
Alzheimer Disease
Pharmacokinetics
Tacrine
Aptitude
Nicotinic Receptors
Acetylcholinesterase
Pharmaceutical Preparations
Half-Life
Pathology
Safety
Therapeutics
donepezil

Keywords

  • Acetylcholinesterase inhibitors
  • Donepezil
  • Galantamine
  • Rivastigmine
  • Switching

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{33ef9ba1e70a4b2ab9bd69ae9d96b461,
title = "Pharmacokinetic profiles of current therapies for Alzheimer's disease: Implications for switching to galantamine",
abstract = "Although no pharmacologic treatments have been proved to alter the pathology of Alzheimer's disease, acetylcholinesterase inhibitor (AChEI) therapy offers symptomatic improvements in or delays in the progression of cognitive, behavioral, and functional deficits. Tacrine, donepezil, rivastigmine, and galantamine are the best studied agents in this class. These drugs have varying pharmacokinetic, safety, and tolerability profiles that can affect patient outcomes. Specifically, certain metabolic parameters (ie, half-life and route of metabolism/elimination) can affect a drug's tolerability and become important when a switch from one agent to another is contemplated. The mechanism of action of galantamine, the most recently approved AChEI, varies from that of the other AChEIs in that it has allosteric modulating activity at nicotinic receptors in addition to its ability to inhibit acetylcholinesterase. Benefits of this dual mode of action on the effects of the disease have been suggested.",
keywords = "Acetylcholinesterase inhibitors, Donepezil, Galantamine, Rivastigmine, Switching",
author = "Martin Farlow",
year = "2001",
doi = "10.1016/S0149-2918(01)80164-8",
language = "English",
volume = "23",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "SUPPL. A",

}

TY - JOUR

T1 - Pharmacokinetic profiles of current therapies for Alzheimer's disease

T2 - Implications for switching to galantamine

AU - Farlow, Martin

PY - 2001

Y1 - 2001

N2 - Although no pharmacologic treatments have been proved to alter the pathology of Alzheimer's disease, acetylcholinesterase inhibitor (AChEI) therapy offers symptomatic improvements in or delays in the progression of cognitive, behavioral, and functional deficits. Tacrine, donepezil, rivastigmine, and galantamine are the best studied agents in this class. These drugs have varying pharmacokinetic, safety, and tolerability profiles that can affect patient outcomes. Specifically, certain metabolic parameters (ie, half-life and route of metabolism/elimination) can affect a drug's tolerability and become important when a switch from one agent to another is contemplated. The mechanism of action of galantamine, the most recently approved AChEI, varies from that of the other AChEIs in that it has allosteric modulating activity at nicotinic receptors in addition to its ability to inhibit acetylcholinesterase. Benefits of this dual mode of action on the effects of the disease have been suggested.

AB - Although no pharmacologic treatments have been proved to alter the pathology of Alzheimer's disease, acetylcholinesterase inhibitor (AChEI) therapy offers symptomatic improvements in or delays in the progression of cognitive, behavioral, and functional deficits. Tacrine, donepezil, rivastigmine, and galantamine are the best studied agents in this class. These drugs have varying pharmacokinetic, safety, and tolerability profiles that can affect patient outcomes. Specifically, certain metabolic parameters (ie, half-life and route of metabolism/elimination) can affect a drug's tolerability and become important when a switch from one agent to another is contemplated. The mechanism of action of galantamine, the most recently approved AChEI, varies from that of the other AChEIs in that it has allosteric modulating activity at nicotinic receptors in addition to its ability to inhibit acetylcholinesterase. Benefits of this dual mode of action on the effects of the disease have been suggested.

KW - Acetylcholinesterase inhibitors

KW - Donepezil

KW - Galantamine

KW - Rivastigmine

KW - Switching

UR - http://www.scopus.com/inward/record.url?scp=0034995980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034995980&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(01)80164-8

DO - 10.1016/S0149-2918(01)80164-8

M3 - Article

C2 - 11396867

AN - SCOPUS:0034995980

VL - 23

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - SUPPL. A

ER -